image
Healthcare - Biotechnology - NASDAQ - US
$ 17.44
-2.57 %
$ 419 M
Market Cap
8.3
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PRTC stock under the worst case scenario is HIDDEN Compared to the current market price of 17.4 USD, PureTech Health plc is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PRTC stock under the base case scenario is HIDDEN Compared to the current market price of 17.4 USD, PureTech Health plc is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PRTC stock under the best case scenario is HIDDEN Compared to the current market price of 17.4 USD, PureTech Health plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PRTC

image
$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
4.32 M REVENUE
29.58%
-136 M OPERATING INCOME
6.91%
27.8 M NET INCOME
142.29%
-134 M OPERATING CASH FLOW
-26.86%
241 M INVESTING CASH FLOW
249.16%
-17 M FINANCING CASH FLOW
-21.70%
4.03 M REVENUE
1298.26%
-69.7 M OPERATING INCOME
-4.97%
69.6 M NET INCOME
266.51%
-54.4 M OPERATING CASH FLOW
32.07%
-232 M INVESTING CASH FLOW
-49.07%
22.1 M FINANCING CASH FLOW
156.63%
Balance Sheet PureTech Health plc
image
Current Assets 386 M
Cash & Short-Term Investments 367 M
Receivables 12.9 M
Other Current Assets 6.05 M
Non-Current Assets 216 M
Long-Term Investments 107 M
PP&E 15.1 M
Other Non-Current Assets 94.1 M
60.95 %17.78 %15.61 %Total Assets$602.6m
Current Liabilities 41.4 M
Accounts Payable 5.52 M
Short-Term Debt 7.69 M
Other Current Liabilities 28.2 M
Non-Current Liabilities 153 M
Long-Term Debt 14.7 M
Other Non-Current Liabilities 139 M
2.84 %3.95 %14.47 %7.54 %71.21 %Total Liabilities$194.7m
EFFICIENCY
Earnings Waterfall PureTech Health plc
image
Revenue 4.32 M
Cost Of Revenue 0
Gross Profit 4.32 M
Operating Expenses 140 M
Operating Income -136 M
Other Expenses -164 M
Net Income 27.8 M
40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)4m04m(140m)(136m)164m28mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-3154.00% OPERATING MARGIN
-3154.00%
1240.09% NET MARGIN
1240.09%
12.90% ROE
12.90%
8.88% ROA
8.88%
-27.95% ROIC
-27.95%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis PureTech Health plc
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 27.8 M
Depreciation & Amortization 3.57 M
Capital Expenditures -11 K
Stock-Based Compensation 22.8 M
Change in Working Capital -10.2 M
Others -189 M
Free Cash Flow -134 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets PureTech Health plc
image
Wall Street analysts predict an average 1-year price target for PRTC of $54.2 , with forecasts ranging from a low of $37 to a high of $70 .
PRTC Lowest Price Target Wall Street Target
37 USD 112.16%
PRTC Average Price Target Wall Street Target
54.2 USD 211.07%
PRTC Highest Price Target Wall Street Target
70 USD 301.38%
Price
Max Price Target
Min Price Target
Average Price Target
7070606050504040303020201010Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership PureTech Health plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
PureTech Health: Results of Annual General Meeting BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting. businesswire.com - 2 weeks ago
PureTech to Present at the Jefferies Global Healthcare Conference BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference. businesswire.com - 1 month ago
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF) BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF). businesswire.com - 1 month ago
PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript PureTech Health plc (NASDAQ:PRTC ) Q4 2024 Earnings Call April 30, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior Vice President, Communications Bharatt Chowrira - Chief Executive Officer Eric Elenko - Co-Founder and President Conference Call Participants Miles Dixon - Peel Hunt Faisal Khurshid - Leerink Partners Operator Greetings and welcome to the PureTech Health 2024 Year End Financial Results Conference. [Operator Instructions] As a reminder, this conference is being recorded. seekingalpha.com - 2 months ago
PureTech Announces Annual Results for Year Ended December 31, 2024 BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2024. businesswire.com - 2 months ago
PureTech Health: Notice of Results BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results. businesswire.com - 2 months ago
PureTech Appoints Peel Hunt as Joint UK Corporate Broker BOSTON--(BUSINESS WIRE)--PureTech Appoints Peel Hunt as Joint UK Corporate Broker. businesswire.com - 2 months ago
PureTech Health plc Statement Regarding Press Speculation BOSTON--(BUSINESS WIRE)--Statement regarding press speculation. businesswire.com - 2 months ago
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform. businesswire.com - 4 months ago
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine BOSTON--(BUSINESS WIRE)--PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine. businesswire.com - 5 months ago
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) BOSTON--(BUSINESS WIRE)--PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML). businesswire.com - 5 months ago
PureTech Appoints UBS as UK Corporate Broker BOSTON--(BUSINESS WIRE)--PureTech Appoints UBS as UK Corporate Broker. businesswire.com - 5 months ago
8. Profile Summary

PureTech Health plc PRTC

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 419 M
Dividend Yield 0.00%
Description PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Contact 6 Tide Street, Boston, MA, 02210 https://www.puretechhealth.com
IPO Date Nov. 16, 2020
Employees 80
Officers Mr. Spencer Ball Executive Vice President of Human Resources Mr. Michael Inbar CPA, M.B.A. Chief Accounting Officer Ms. Daphne Zohar Founder, Senior Advisor & Board Observer Dr. Eric Elenko Ph.D. Co-Founder & President Ms. Lauren A. White M.B.A. Chief Financial Officer Ms. Allison Mead Talbot Senior Vice President of Communications & Head of Investor Relations Mr. Charles Sherwood III, J.D., Ph.D. General Counsel & Company Secretary Dr. Bharatt M. Chowrira J.D., Ph.D. Chief Executive Officer & Executive Director Dr. Robert S. Langer Jr., Ph.D., ScD Co-Founder & Non-Executive Director Dr. David R. Elmaleh Ph.D. Co-Founder & Senior Advisor